Request that the FDA establish a clear process that provides sponsors with notice and an opportunity to respond to proposed disclosures of CRLs associated with unapproved new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license applications (BLAs) and supplements and amendments thereto (herein, applications) | Federal Regulations · Congress.wiki